In colorectal cancer (CRC), PIK3CA mutations have been shown to reprogram glutamine metabolism by upregulating glutamate pyruvate transaminase 2 (GPT2), thereby increasing tumor cell dependence on glutamine. The gene discussed is GPT2; the disease is colorectal cancer.